LivaNova (NASDAQ:LIVN) Price Target Cut to $60.00 by Analysts at Stifel Nicolaus

LivaNova (NASDAQ:LIVN) had its price target cut by Stifel Nicolaus from $72.00 to $60.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. Needham & Company LLC lowered their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Finally, Robert W. Baird upped their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LivaNova has a consensus rating of “Buy” and an average target price of $64.20.

LivaNova Price Performance

NASDAQ LIVN opened at $41.45 on Wednesday. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of 98.69 and a beta of 1.00. LivaNova has a 12 month low of $40.37 and a 12 month high of $64.47. The company’s 50 day moving average is $47.65 and its two-hundred day moving average is $49.56. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of LivaNova

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock worth $108,823,000 after acquiring an additional 265,291 shares during the period. Point72 Asset Management L.P. grew its stake in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Capital Research Global Investors increased its holdings in LivaNova by 19.1% during the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock worth $74,690,000 after purchasing an additional 258,730 shares during the period. Geode Capital Management LLC raised its position in LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of LivaNova by 8.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after buying an additional 107,693 shares during the period. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.